| 7.92 -0.42 (-5.04%) | 12-05 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 10.97  |
1-year : | 12.73 |
| Resists | First : | 9.39 |
Second : | 10.89 |
| Pivot price | 8.69 |
|||
| Supports | First : | 6.96 |
Second : | 5.79 |
| MAs | MA(5) : | 8.35 |
MA(20) : | 8.99 |
| MA(100) : | 7.47 |
MA(250) : | 0 | |
| MACD | MACD : | 0 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 5.4 |
D(3) : | 8.9 |
| RSI | RSI(14): 42.1 |
|||
| 52-week | High : | 13.52 | Low : | 5.63 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ DAWN ] has closed above bottom band by 6.6%. Bollinger Bands are 6.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 8.51 - 8.56 | 8.56 - 8.6 |
| Low: | 7.77 - 7.83 | 7.83 - 7.88 |
| Close: | 7.83 - 7.92 | 7.92 - 8 |
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Sun, 07 Dec 2025
180,133 Shares in Day One Biopharmaceuticals, Inc. $DAWN Bought by Schroder Investment Management Group - MarketBeat
Thu, 04 Dec 2025
Day One Biopharmaceuticals, Inc. $DAWN Shares Purchased by Geode Capital Management LLC - MarketBeat
Mon, 24 Nov 2025
HC Wainwright & Co. Reiterates Day One Biopharmaceuticals (DAWN) Buy Recommendation - Nasdaq
Mon, 17 Nov 2025
Wall Street Analysts Believe Day One Biopharmaceuticals (DAWN) Could Rally 161.36%: Here's is How to Trade - Nasdaq
Fri, 14 Nov 2025
Day One Biopharmaceuticals (DAWN): Examining Valuation Following Recent Share Price Rebound - Yahoo Finance
Thu, 13 Nov 2025
Day One Biopharmaceuticals: Mersana Acquisition Ignites March Towards Unmet Need (DAWN) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 103 (M) |
| Shares Float | 79 (M) |
| Held by Insiders | 16.9 (%) |
| Held by Institutions | 84.1 (%) |
| Shares Short | 8,970 (K) |
| Shares Short P.Month | 10,060 (K) |
| EPS | -1.52 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.38 |
| Profit Margin | -113.6 % |
| Operating Margin | -61 % |
| Return on Assets (ttm) | -18.6 % |
| Return on Equity (ttm) | -30.2 % |
| Qtrly Rev. Growth | -57.6 % |
| Gross Profit (p.s.) | 1.16 |
| Sales Per Share | 1.3 |
| EBITDA (p.s.) | -1.59 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -120 (M) |
| Levered Free Cash Flow | -60 (M) |
| PE Ratio | -5.22 |
| PEG Ratio | 0 |
| Price to Book value | 1.8 |
| Price to Sales | 6.08 |
| Price to Cash Flow | -6.8 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|